Determination of the Re-188 Calibration Number for the Capintec CRC- 25PET Dose Calibrator.

IF 1.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Current radiopharmaceuticals Pub Date : 2023-01-01 DOI:10.2174/1874471016666230502140224
Mitchell Ashley Klenner, Aron Poole
{"title":"Determination of the Re-188 Calibration Number for the Capintec CRC- 25PET Dose Calibrator.","authors":"Mitchell Ashley Klenner,&nbsp;Aron Poole","doi":"10.2174/1874471016666230502140224","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>During the development of novel Re-188 radiopharmaceuticals, it was discovered that no calibration settings were published to calibrate Re-188 on the Capintec CRC-25PET dose calibrator.</p><p><strong>Methods: </strong>Sodium [<sup>188</sup>Re]perrhenate was eluted from an OncoBeta <sup>188</sup>W/<sup>188</sup>Re generator to measure activity on a Capintec CRC-25R dose calibrator using established dose calibrator settings provided by the manufacturer. The eluent was then used to tune the calibra on settings on a Capintec CRC-25PET dose calibrator, accounting for geometry. Radionuclidic purity of the [<sup>188</sup>Re]perrhenate source was verified via gamma spectroscopy.</p><p><strong>Results: </strong>The calibrator number for Re-188 was determined to be 469 x 10 for the Capintec CRC-25PET dose calibrator, which differed from the manufacturer provided calibra on number of 496 x 10 for the Capintec CRC-25R dose calibra on model. W-188 breakthrough was characterised as < 0.01%.</p><p><strong>Conclusion: </strong>This previously unreported calibration number can be used to determine the activity of Re- 188 labelled radiopharmaceuticals using the Capintec CRC-25PET dose calibrator model.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 4","pages":"292-299"},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1874471016666230502140224","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: During the development of novel Re-188 radiopharmaceuticals, it was discovered that no calibration settings were published to calibrate Re-188 on the Capintec CRC-25PET dose calibrator.

Methods: Sodium [188Re]perrhenate was eluted from an OncoBeta 188W/188Re generator to measure activity on a Capintec CRC-25R dose calibrator using established dose calibrator settings provided by the manufacturer. The eluent was then used to tune the calibra on settings on a Capintec CRC-25PET dose calibrator, accounting for geometry. Radionuclidic purity of the [188Re]perrhenate source was verified via gamma spectroscopy.

Results: The calibrator number for Re-188 was determined to be 469 x 10 for the Capintec CRC-25PET dose calibrator, which differed from the manufacturer provided calibra on number of 496 x 10 for the Capintec CRC-25R dose calibra on model. W-188 breakthrough was characterised as < 0.01%.

Conclusion: This previously unreported calibration number can be used to determine the activity of Re- 188 labelled radiopharmaceuticals using the Capintec CRC-25PET dose calibrator model.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Capintec CRC- 25PET剂量校准器Re-188校准号的确定。
背景:在新型Re-188放射性药物的开发过程中,发现Capintec CRC-25PET剂量校准器上没有发布校准设置来校准Re-188。方法:从OncoBeta 188W/188Re发生器中洗脱过透酸钠[188Re],在Capintec CRC-25R剂量校准器上使用制造商提供的剂量校准器设置测量活性。然后使用该洗脱液调整Capintec CRC-25PET剂量校准器上的刻度设置,考虑几何形状。通过伽玛谱法验证了[188Re]过铼酸盐源的放射性核素纯度。结果:Capintec CRC-25PET剂量校准器的Re-188校准器编号为469 × 10,不同于制造商提供的型号Capintec CRC-25R剂量校准器编号为496 × 10。W-188突破特征为< 0.01%。结论:此先前未报道的校准数可用于使用Capintec CRC-25PET剂量校准器模型确定Re- 188标记的放射性药物的活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current radiopharmaceuticals
Current radiopharmaceuticals PHARMACOLOGY & PHARMACY-
CiteScore
3.20
自引率
4.30%
发文量
43
期刊最新文献
Enhancing Ketoprofen Solubility: A Strategic Approach Using Solid Dispersion and Response Surface Methodology. Preclinical Aspects of [89Zr]Zr-DFO-Rituximab: A High Potential Agent for Immuno-PET Imaging. Apigenin's Influence on Inflammatory and Epigenetic Responses in Rat Lungs After Radiotherapy. An Analysis of the Radiosensitiser Applications in the Biomedical Field. Left Ventricular Wall Motion as an Additional Valuable Parameter in Diabetic Patients with Normal Myocardial Perfusion Imaging.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1